Introduction {#Sec1}
============

Neoadjuvant chemoradiation (CRT) followed by radical resection is now recommended for locally advanced rectal cancer \[[@CR1]\], which brings meaningful tumor shrinking, down staging, improved local control, and increased probability of sphincter-sparing surgery \[[@CR2]--[@CR5]\]. However, the degree of response to CRT, with its clinical significance in predicting the long-term outcome, varied among patients \[[@CR6]\]. Patients who exhibited favorable response (ypT0--2N0) were reported to achieve excellent survival regardless of receiving adjuvant chemotherapy or not. Postoperative adjuvant chemotherapy, though typically recommended for all by NCCN guidelines, seemed to contribute little to improve the survival for these patients \[[@CR6]--[@CR10]\].

Currently, the delivery of adjuvant chemotherapy for rectal cancer patients undergoing chemoradiation is not evidence based \[[@CR11]\]. Several studies have questioned the need of adjuvant chemotherapy for ypN0 patients, especially for those with ypT0--2 \[[@CR8]--[@CR10], [@CR12]\]. However, it is still a controversial problem \[[@CR8]--[@CR10], [@CR12]--[@CR14]\]. The purpose of this study was to re-evaluate the role of adjuvant chemotherapy in patients with ypN0. We explored some clinical factors in predicting the prognosis for patients in this subgroup.

Materials and methods {#Sec2}
=====================

Ethics statement {#Sec3}
----------------

This research was approved by the Ethics Committee of Sun Yat-sen University Cancer Center, and the written informed consent was obtained from every patient included in the study.

Patients {#Sec4}
--------

We conducted a retrospective study of 237 patients who had undergone CRT followed by surgery at the cancer center of Sun Yat-sen University between March 2003 and November 2010. All the patients had locally advanced rectal cancer as shown by biopsy. There were 27 patients excluded for concurrent distant metastasis, concurrent malignancy, or prior history of radiotherapy to the pelvis. Finally, 160 patients with pathology of ypN0 were enrolled in this study.

Evaluation {#Sec5}
----------

Before CRT, all patients underwent staging workup, which included endorectal ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and chest radiography. Endorectal ultrasound was typically recommended for patients for its accurate T staging in our cancer center. Abdominal CT and chest radiography are routine examinations with at least CT or MRI for the pelvis. Pre-CRT Serum CEA, complete blood count, and liver function test were also measured.

Treatment {#Sec6}
---------

Patients underwent a standard protocol of CRT with two courses of concurrent chemotherapy. The prescription dose to the whole pelvis was 46 Gy in 23 fractions over 5 weeks. The technique of radiotherapy was based on a three-dimensional conformal radiotherapy treatment planning system (PINNACLE 8) with a three-field irradiation plan being used (8-MV photon posterior--anterior field and 15-MV photon opposed lateral beams). The clinical target volume (CTV) included primary rectal tumor, peri-rectal tissues, presacral lymph nodes, internal iliac lymph nodes, and obturator lymph nodes. The superior border of the CTV was the bottom of L5, and the inferior border was 2.5--3 cm distal to the tumor. The anterior border was the posterior margin of the bladder or uterus, and the posterior border was the anterior margin of the sacrum. PTV is defined as CTV + 8∼10 mm.

The regimens of concurrent chemotherapy were Folfox6 and Xelox. There were 37 patients who were treated with chemotherapy of Folfox6 (oxaliplatin 85 mg/m^2^ day 1 + leucovorin 400 mg/m^2^ day 1 + 5-FU 400 mg/m^2^ iv day 1, then 2,400 mg/m^2^ civ 46--48 h), while the other 123 patients received Xelox (oxaliplatin 100 mg/m^2^ day 1 + capecitabine 1,000 mg/m^2^ bid, po, days 1--14).

At a median of 43 days (range, 20--73) after the completion of chemoradiotherapy, radical surgery for rectal cancer was implemented. All the operations were performed according to the TME-principles by colorectal surgeons, and the methods included low anterior resection, abdominoperineal resection, and Hartmann. Negative circumferential resection margin proved by pathology was achieved by all the patients in this study.

Adjuvant chemotherapy were administrated in 115 patients with the regimens of Folfox6 (oxaliplatin 85 mg/m^2^ day 1 + leucovorin 400 mg/m^2^ day 1 + 5-FU 400 mg/m^2^ iv day 1, then 2,400 mg/m^2^ civ 46--48 h), Xelox (oxaliplatin 130 mg/m^2^ day 1 + capecitabine 1,000 mg/m^2^ bid, po, days 1--14), and single agent capecitabine (capecitabine 1,250 mg/m^2^ bid, po, days 1--14). The median month of adjuvant chemotherapy was 4 (range, 2--7.5). The other 45 patients were not scheduled with adjuvant chemotherapy due to various reasons such as, severe postoperative complications, poor performance status, or refusal due to elder age.

Pathological classification {#Sec7}
---------------------------

Pathological tumor staging of the resected specimen was performed by experienced pathologists. The operative specimens of 160 patients were restaged by two independent pathologists according to the American Joint Committee on Cancer (AJCC) 7th edition staging system. If their stagings were inconsistent, then a third pathologist was needed to perform the task. All the specimens were carefully dissected by the pathologists to achieve all the potential lymph nodes, and the median of retrieved lymph nodes was 8 (range, 3--37).

Toxicity assessment for neoadjuvant chemoradiation and adjuvant chemotherapy {#Sec8}
----------------------------------------------------------------------------

Therapy-related adverse events were defined as complications that occurred during treatment, which were graded by using the Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Severe adverse events were defined as any grade ≥3 toxicity. Adverse events were recorded for each patient treated in our cancer center and were documented in our colonrectal database.

Follow-up {#Sec9}
---------

The follow-up policy was every 3 months for the first 2 years after surgery and every 6 months thereafter. However, during the period of postoperative adjuvant chemotherapy, the follow-up was delayed until the completion of all treatments. Evaluations included complete blood count, liver function test, CEA, CA19-9, and physical examination during each visit. Chest radiography, CT scanning of the abdomen and pelvis, and colonoscopy were conducted every 6 months. Every follow-up for each patient was recorded in our database. In this study, the median follow-up period for all patients was 46 months (range, 18--101).

Statistical analysis {#Sec10}
--------------------

All statistical analyses were performed by SPSS software, version 17.0. Categorical variables were analyzed by using the chi-square test or Fisher's exact test. Continuous variables were analyzed by the Student *t* test or Mann--Whitney *U* test. The Kaplan--Meier method was employed to compare DFS rates and OS rates. Multivariate analysis of DFS, LRFS, and DMFS was performed by Cox proportional hazards regression, and the Cox proportional hazards model was performed using a forward conditional selection of variables. Variables with *P* value \< 0.2 were entered into a Cox model. *P* \< 0.05 was considered to be statistically significant.

Results {#Sec11}
=======

Clinical characteristics {#Sec12}
------------------------

There were 160 patients who completed CRT and were node-negative on the final pathology enrolled in our study. Among them, 115 patents received postoperative adjuvant chemotherapy, while 45 patents did not. Compared to patients who received adjuvant chemotherapy, those who did not were significantly older (*P* \< 0.001) and more likely to receive the concurrent chemotherapy of Folfox6 (*P* = 0.011). Other variables such as gender, Hb, CEA, location of tumor, clinical tumor stage, clinical T stage, clinical N stage, tumor grade, interval between completion of chemoradiotherapy and surgery, type of surgery, number of retrieved lymph nodes, ypT stage, and follow-up were similar between two groups (Table [1](#Tab1){ref-type="table"}).Table 1Patient demographics, baseline tumor characteristics, type of surgery, and pathological outcomeVariableAdjuvant-chemo groupNo adjuvant-chemo group*P* valueAge, year----\<0.001 Median54 (15--80)62 (39--77)--Gender----0.552 Male8732-- Female2813--Hb, g/L----0.575 Average129 (78--170)126 (76--160)--CEA, μg/mL----0.081 Median4.95 (0.20--157.50)3.33 (0.54--249.60)--Location of tumor, from AV----1.000 ≥7.0 cm20 (17.4 %)7 (15.6 %)-- \<7.0 cm95 (82.6 %)38 (84.4 %)--Clinical T stage----1.000 T12 (1.7 %)0 (0.0 %)-- T23 (2.6 %)1 (2.2 %)-- T346 (40.0 %)18 (40.0 %)-- T4 (T4a and T4b)64 (55.7 %)26 (57.8 %)--Clinical N stage----0.612 N041 (35.7 %)20 (44.4 %)-- N130 (26.1 %)10 (22.2 %)-- N244 (38.2 %)15 (23.4 %)--Clinical stage----0.366 II41 (35.7 %)20 (44.4 %)-- III74 (64.3 %)25 (55.6 %)--Tumor grade----0.743 G19 (7.8 %)4 (8.9 %)-- G287 (75.7 %)36 (80.0 %)-- G319 (16.5 %)5 (11.1 %)--Concurrent chemotherapy----0.011 Folfox620 (17.4 %)17 (37.8 %)-- Xelox95 (82.6 %)28 (62.2 %)--Interval, day----0.588 Median4244--Type of surgery----0.734 Mile's56 (48.7 %)20 (48.9 %)-- Dixon58 (50.4 %)22 (48.9 %)-- Hartmann1 (0.9 %)1 (0.2 %)--Retrieved lymph nodes Median870.234 ypT stage----0.603  ypT039 (33.9 %)13 (28.9 %)--  ypT12 (1.7 %)3 (6.7 %)--  ypT224 (20.9 %)10 (22.2 %)--  ypT337 (34.8 %)16 (35.6 %)--  ypT4a10 (8.7 %)3 (6.7 %)--Follow-up, months----0.710 Median4741--Tumor grade: G1 = well differentiated, G2 = moderately differentiated, G3 = poorly differentiated*Adjuvant-chemo* adjuvant chemotherapy, *Hb* hemoglobin, *CEA* carcinoembryonic antigen, *AV* anal verge

Survival analysis {#Sec13}
-----------------

For the whole group, the median follow-up was 46 months and the 5-year OS and DFS in the adjuvant and non-adjuvant chemotherapy groups were 87.0, 85.5 % and 70.6, 67.4 %, respectively (Table [2](#Tab2){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Further analysis showed that the 5-year OS and DFS were similar between patients who did and did not receive adjuvant chemotherapy in the ypT0--2N0 subgroup (Table [3](#Tab3){ref-type="table"}; Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). However, for patients with ypT3--4N0, receiving adjuvant chemotherapy had the tendency to acquire higher OS and DFS than those who did not (Table [4](#Tab4){ref-type="table"}; Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}).Table 2OS and DFS for patients with ypT0--4N0GroupAdjuvant-chemo groupNo adjuvant-chemo group*P* value3-year5-year3-year5-yearOS93.6 %87.0 %90.5 %70.6 %0.052DFS91.7 %85.5 %76.2 %67.4 %0.059*Adjuvant-chemo* adjuvant chemotherapy, *DFS* disease-free survival, *OS* overall survivalFig. 1OS for the ypT0--4N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in OS between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--4N0 patients (*P* = 0.052)Fig. 2DFS for the ypT0--4N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in DFS between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--4N0 patients (*P* = 0.059)Table 3OS and DFS for patients with ypT0--2N0GroupAdjuvant-chemo groupNo adjuvant-chemo group*P* value3-year5-year3-year5-yearOS93.7 %93.7 %96.2 %83.7 %0.401DFS92.2 %85.8 %80.4 %73.1 %0.359*Adjuvant-chemo* adjuvant chemotherapy, *DFS* disease-free survival, *OS* overall survivalFig. 3OS for the ypT0--2N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in OS between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--2N0 patients (*P* = 0.401)Fig. 4DFS for the ypT0--2N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in DFS between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--2N0 patients (*P* = 0.359)Table 4OS and DFS for patients with ypT3--4N0GroupAdjuvant-chemo groupNo adjuvant-chemo group*P* value3-year5-year3-year5-yearOS93.6 %81.1 %82.1 %49.3 %0.026DFS88.3 %84.8 %71.1 %59.2 %0.050*Adjuvant-chemo* adjuvant chemotherapy, *DFS* disease-free survival, *OS* overall survivalFig. 5OS for the ypT3--4N0 patients stratified by treatment with adjuvant chemotherapy. The OS was significantly higher in adjuvant-chemotherapy group than that in no adjuvant-chemotherapy group for ypT3--4N0 patients (*P* = 0.026)Fig. 6DFS for ypT3--4N0 patients stratified by treatment with adjuvant chemotherapy. The DFS was significantly higher in adjuvant-chemotherapy group than that in no adjuvant-chemotherapy group for ypT3--4N0 patients (*P* = 0.050)

Recurrence analysis {#Sec14}
-------------------

During the follow-up, 25 patients recurred. Among them, local failure occurred in eight patients, and distant failure occurred in 17 patients. For the subgroup of ypT0--2N0, no differences were found in both local and distant recurrences between patients who received adjuvant chemotherapy and those who did not (Table [5](#Tab5){ref-type="table"}; Figs. [7](#Fig7){ref-type="fig"} and [8](#Fig8){ref-type="fig"}). In ypT3--4N0 subgroup, though patients given no adjuvant chemotherapy did not show increased risk of local recurrence than those who were given, distant metastases rates were significant higher in these patients (Table [6](#Tab6){ref-type="table"}; Fig. [9](#Fig9){ref-type="fig"}).Table 5Recurrence patterns for patients with ypT0--2N0GroupAdjuvant-chemo group (*n* = 65)No adjuvant-chemo group (*n* = 26)*P* value3-year5-year3-year5-yearLR4 (6.2 %)5 (7.7 %)2 (7.7 %)2 (7.7 %)1.000SM1 (1.5 %)2 (3.1 %)2 (7.7 %)3 (11.5 %)0.153*Adjuvant-chemo* adjuvant chemotherapy, *LR* local recurrence, *SM* systemic metastasesFig. 7Cumulative hazard of local recurrence for ypT0--2N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in cumulative hazard of local recurrence between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--2N0 patients (*P* = 1.000)Fig. 8Cumulative hazard of systemic metastases for ypT0--2N0 patients stratified by treatment with adjuvant chemotherapy. No significant difference was found in cumulative hazard of systemic metastases between adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0--2N0 patients (*P* = 0.153)Table 6Recurrence patterns for patients with ypT3--4N0GroupAdjuvant-chemo group (*n* = 50)No adjuvant-chemo group (*n* = 19)*P* value3-year5-year3-year5-yearLR1 (2.0 %)1 (2.0 %)0 (0.0 %)0 (0.0 %)0.538SM4 (8.0 %)6 (12.0 %)5 (26.3 %)6 (31.6 %)0.026*Adjuvant-chemo* adjuvant chemotherapy, *LR* local recurrence, *SM* systemic metastasesFig. 9Cumulative hazard of systemic metastases for ypT3--4N0 patients stratified by treatment with adjuvant chemotherapy. The cumulative hazard of systemic metastases was significantly higher in no adjuvant-chemotherapy group than that in adjuvant-chemotherapy group for ypT3--4N0 patients (*P* = 0.026)

Clinical predictors for DFS, LRFS, and DMFS {#Sec15}
-------------------------------------------

In multivariable analysis, both the final pathological stage and adjuvant chemotherapy were independent predictors of DMFS for the whole group (ypT0--4N0) but with no clinical factors found to be associated with LRFS (Table [7](#Tab7){ref-type="table"}). When stratified by pathological stage, no clinical factor were found to predict that LRFS adjuvant chemotherapy was still significantly associated with DMFS with the adjusted HR of 0.297 (95 % CI 0.095 to 0.924, *P* = 0.036), in the ypT3--4 stratum (Table [8](#Tab8){ref-type="table"}).Table 7Multivariate analyses of DFS, LRFS, and DMFS for ypT0--4 patientsVariableDFSLRFSDMFSHR (95 % CI)*P* valueHR (95 % CI)*P* valueHR (95 % CI)*P* valueyp T stage ypT0--2 vs ypT3--4NA5.264 (0.648--42.791)0.1200.267 (0.094--0.761)0.014Adjuvant-chemo yes vs no0.476 (0.216--1.050)0.066NA0.294 (0.113--0.766)0.012*DFS* disease-free survival, *LRFS* local recurrence-free survival, *DMFS* distant metastasis-free survival, *NA* not available, *CI* confidence interval, *HR* hazard ratio, *Adjuvant-chemo* Adjuvant chemotherapyTable 8Multivariable analyses of DFS, LRFS, and DMFS for ypT3--4 patientsVariableDFSLRFSDMFSHR (95 % CI)*P* valueHR (95 % CI)*P* valueHR (95 % CI)*P* valueyp T stage ypT0--2 vs ypT3--4NANANAAdjuvant-chemo yes vs no0.354 (0.118--1.057)0.063NA0.297 (0.095--0.924)0.036*DFS* disease-free survival, *LRFS* local recurrence-free survival, *DMFS* distant metastasis-free survival, *NA* not available, *CI* confidence interval, *HR* hazard ratio. *Adjuvant-chemo* adjuvant chemotherapy

Toxicity of chemoradiation and adjuvant chemotherapy {#Sec16}
----------------------------------------------------

During the neoadjuvant chemoradiation, the most common toxicity types observed were diarrhea, neutropenia, and abdominal pain, and major severe adverse events (grade ≥ 3) included diarrhea (15.0 %), enteritis (12.6 %), and neurotoxity (5.6 %) (Table [9](#Tab9){ref-type="table"}). However, the most common toxicity types for adjuvant chemotherapy were diarrhea, hand--foot syndrome, and neutropenia. Severe adverse events, during the adjuvant chemotherapy, were observed most in the toxicity types of diarrhea (17.4 %), nausea (4.3 %), and neurotoxity (4.3 %) (Table [10](#Tab10){ref-type="table"}). No patents died of severe adverse events.Table 9Toxicity of chemoradiationToxicity typeGrade1∼2345≥3Abdominal distension20 (12.5 %)4 (2.5 %)NANA4 (2.5 %)Abdominal pain57 (35.6 %)3 (1.9 %)003 (1.9 %)Nausea40 (25 %)6 (3.8 %)006 (3.8 %)Vomiting33 (20.6 %)5 (3.1 %)005 (3.1 %)Enteritis30 (18.8 %)18 (11.3 %)2 (1.3 %)020 (12.6 %)Diarrhea60 (37.5 %)20 (12.5 %)4 (2.5 %)024 (15.0 %)Constipation44 (27.5 %)5 (3.1 %)3 (1.9 %)08 (5.0 %)Neurotoxity34 (21.3 %)9 (5.6 %)009 (5.6 %)Hand--foot syndrome56 (35.0 %)3 (1.9 %)NANA3 (1.9 %)Hemoglobin27 (16.9 %)1 (0.6 %)001 (0.6 %)Neutrophils73 (45.6 %)7 (4.4 %)007 (4.4 %)Platelets20 (12.5 %)2 (1.3 %)002 (1.3 %)*NA* not availableTable 10Toxicity of adjuvant chemotherapyToxicity typeGrade1∼2345≥3Abdominal distension7 (6.1 %)0NANA0Abdominal pain11 (9.6 %)1 (0.9 %)001 (0.9 %)Nausea30 (26.1 %)5 (4.3 %)005 (4.3 %)Vomiting20 (17.4 %)3 (2.6 %)003 (2.6 %)Enteritis7 (6.1 %)2 (1.7 %)002 (1.7 %)Diarrhea45 (39.1 %)18 (15.7 %)2 (1.7 %)020 (17.4 %)Constipation28 (24.3 %)1 (0.9 %)001 (0.9 %)Neurotoxity18 (15.7 %)5 (4.3 %)005 (4.3 %)Hand--foot syndrome48 (41.7 %)3 (2.6 %)NANA3 (2.6 %)Hemoglobin13 (11.3 %)0000Neutrophils46 (40.0 %)2 (1.7 %)002 (1.7 %)Platelets6 (5.2 %)1 (0.9 %)001 (0.9 %)*NA* not available

Discussion {#Sec17}
==========

In our present study, for patients with ypT0--4N0, 5-year OS and DFS in the adjuvant and no adjuvant-chemotherapy groups were 87.0, 85.5 % and 70.6, 67.4 %, respectively, with both the *P* values close to 0.050. Further subgroup analysis showed that postoperative adjuvant chemotherapy did not improve the survival for patients with ypT0--2N0, but for ypT3--4N0 patients, the 5-year OS were higher in the adjuvant-chemotherapy group than no in the adjuvant-chemotherapy group with also a tendency for 5-year DFS; meaning that the postoperative adjuvant chemotherapy may be clinically beneficial for patients with ypT3--4N0.

We then explored the patterns of recurrence for the entire group (ypT0--4N0) and subgroups (ypT0--2N0, ypT3--4N0). The results indicated similar local recurrence rates between patients who were given postoperative adjuvant chemotherapy and those who were not. However, the rates of distant metastases were found higher in no adjuvant-chemotherapy group compared to those in adjuvant-chemotherapy group for ypT3--4N0 patients. This was not shown in ypT0--2N0 patients; revealing that the real benefit of postoperative adjuvant chemotherapy lay in reducing the risk of distant metastasis for those with ypT3--4N0. To adjust other potentially measured confounders such as age and concurrent chemotherapy, multivariate analysis was performed by Cox proportional hazards regression. The results showed that both the final pathological stage and adjuvant chemotherapy were independent predictors of DMFS for the whole group (ypT0--4N0) and with no clinical factors associated with LRFS. After stratified by pathological stage, adjuvant chemotherapy was still significantly associated with DMFS in the ypT3--4N0 stratum, with patients who did not receive adjuvant chemotherapy having a 3.4-fold increased risk of distant metastasis relative to those who did.

The contemporary management of locally advanced rectal cancer is long-course chemoradiation followed by radical resection. No matter what the final pathology is, a full course of adjuvant chemotherapy is recommended. However, there is no sufficient evidence supporting this strategy \[[@CR11]\]. The only clinical randomized controlled studies exploring the significance of chemotherapy given preoperatively or postoperatively for rectal cancer patients receiving preoperative radiotherapy failed to demonstrate that the postoperative adjuvant chemotherapy could significantly improve the OS and DFS \[[@CR4]\]. The study group took a retrospective analysis subsequently with their results revealing that postoperative adjuvant chemotherapy could improve the 5-year OS and DFS for ypT0--2 patients but not for those with ypT3--4. \[[@CR13]\] Their exploratory analysis suggested that same prognostic factor may drive both tumor sensitivity for primary treatment and long-term clinical benefit from further adjuvant chemotherapy. Thus, patients with good response to chemoradiation or radiotherapy may benefit from the later adjuvant chemotherapy, but they may devote all their attention to treatment response, failing to consider the prognosis of patients in the management of adjuvant chemotherapy. Patients with a good response to chemoradiation (ypT0--2N0) have been reported to acquire a favorable outcome regardless of receiving adjuvant chemotherapy or not. The contribution of adjuvant chemotherapy, though seemly effective, did little in improving the survival for ypT0--2N0 patients \[[@CR8]--[@CR10], [@CR12]\]. Patients with ypT3--4 or N+ may need adjuvant chemotherapy for their increased risks of recurrence. Besides, the subsequent study was based only on the pathological T staging in the subgroup analysis and ignoring the pathological N stage, which was considered as a significant prognostic factor for rectal cancer patients who received CRT \[[@CR15]--[@CR18]\].

The role of adjuvant chemotherapy for ypN0 patients was first questioned by Fietkau et al \[[@CR19]\]. In his study, disease-free survival for patients without lymph node metastases (ypN0) was excellent, independent of whether they had received postoperative chemotherapy. Similar results were as reported by Kiran ea al. \[[@CR12]\], whose study included 128 rectal cancer cases with ypT0--4N0. Among these, 58 cases received adjuvant chemotherapy and 70 did not. The rates of local recurrence (*P* = 1.00), DFS (*P* = 0.41), and OS (*P* = 0.52) were comparable between two groups. Therefore, the author put forward a strong challenge to routinely administer adjuvant chemotherapy for postoperative rectal cancer patients with ypN0. Further subgroup analysis of ypN0 was performed by Huh JW et al. \[[@CR9]\], who found that adjuvant chemotherapy did not significantly improve survival for ypT0--2N0 patients. They did not present the results for those with ypT3--4N0. The recurrence rates for ypN0 patients were analyzed by Govindarajan et al. \[[@CR8]\], with the results of ypT0N0 2.7 %, ypT1--2N0 12.3 %, and ypT3--4N0 24.2 %. Though the 5-year DFS were comparable between patients receiving adjuvant chemotherapy and those who did not in subgroups of ypT0N0, ypT1--2N0, and ypT3--4N0, multivariable analysis showed pathological staging as the factor that was most strongly associated variable with recurrence (ypT3--4 vs ypT1--2, *P* \< 0.0001) and that the value of adjuvant chemotherapy for ypT3--4N0 may need more investigation. Our present study showed that both the final pathological stage and adjuvant chemotherapy were significantly associated with distant metastasis for the whole group (ypT0--4N0) in the multivariable analysis. Thus, adjuvant chemotherapy, which was the only independent predictor of DMFS in ypT3--4 stratum when multivariable analysis of subgroups is performed, may be especially needed for the patients with final pathology of ypT3--4N0 to decrease the rates of distant failure.

NCCN recommends 4--6 months of postoperative adjuvant chemotherapy for all the locally rectal cancer patients receiving CRT and with the possible considerations that neo-CRT is a loco-regional therapy that should not, theoretically, control the potential of distant metastasis and that the routine administration of adjuvant chemotherapy for the patients in the seminal randomized trials, our results seemed to disfavor its use for patients with ypT0--2N0 due to its failing in improve survival significantly for these patients. If our conclusions were true, adjuvant chemotherapy may be avoided in approximately 47.0 % patients \[[@CR6]\] who received CRT. This could significantly reduce the toxicity caused by chemotherapy \[[@CR20]--[@CR22]\]. Accordingly, we recommend selective administration of adjuvant chemotherapy for patients with high recurrence risks rather than those with fine prognosis needing further randomized trials to confirm since our conclusions were based on a small sample analysis.

Limitations such as small sample size, short follow-up, and retrospective design were not avoided in our study. Another major problem was the inconformity of regimens and courses of adjuvant chemotherapy, which prevented us from doing further analyses. We had difficulty in excluding the possibility that no better survival was found in ypT0--2 patients receiving adjuvant chemotherapy than those who did not. This was due to the inadequate courses of adjuvant chemotherapy, since the median month of adjuvant chemotherapy was four, but we noticed that seven cases in the ypT0--2N0 subgroup, who had developed recurrence in the adjuvant chemo-group, received at least 4 months of adjuvant chemotherapy, accompanied by five cases with recurrence in the no adjuvant-chemotherapy group. This may support our hypothesis that this was due to the adjuvant chemotherapy itself contributing little or no effect on the survival for ypT0--2N0 patients rather than the courses of it. It was also hard to decide whether the regimen of Xelox could result in a better outcome than that of Folfox6 for ypT3--4N0 patients, which may be analyzed by further subgroup analysis, but with too few cases in each group and unbalanced baseline characteristics between groups, it limited our ability to reveal the possible clinically significant differences.

In conclusion, according to the results of our study and other reports, for locally advanced rectal cancer after CRT and surgery, there is no sufficient evidence supporting that postoperative adjuvant chemotherapy could improve survival for ypT0--2N0 patients. However, adjuvant chemotherapy may be clinically meaningful for ypT3--4N0 patients by decreasing rates of distant metastases, thus leading to a better DFS and OS. We strongly suggest selective use of adjuvant chemotherapy for ypN0 patients. Further randomized controlled clinical trials are needed to address this problem.
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